1. Pink Sheet
  2. >>Regulatory Trackers

Pfizer Push For COVID Vaccine EUA In Ages 5-11 Includes School, Mental Health Arguments

 
• By Derrick Gingery

Briefing documents for the upcoming advisory committee tout potential ‘indirect’ benefits and argue that lower dose should address myocarditis concerns.

Children playing in a school yard
Pfizer wrote in briefing documents that vaccinating children age 5 to 11 could help alleviate educational disruption caused by COVID-19 outbreaks in schools.

In pushing for authorization to give its COVID-19 vaccine to children age 5 to 11, Pfizer Inc./BioNTech SE highlighted the substantial efficacy of its product, but also raised public and mental health arguments, including the return to in-person schooling.

Pfizer is requesting that children age 5 to less than 12 receive a two 10µg doses, the second three weeks after the first

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

More from Regulatory Trackers